A Phase Ib/II Study of Propranolol With Fixed-Dose Pembrolizumab in Patients With Unresectable Stage III and Stage IV Melanoma
Phase of Trial: Phase I/II
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Propranolol (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 01 Nov 2019 Planned End Date changed from 11 Oct 2020 to 11 Oct 2021.
- 01 Nov 2019 Planned primary completion date changed from 11 Oct 2019 to 11 Oct 2020.
- 03 Apr 2019 Results presented at the 110th Annual Meeting of the American Association for Cancer Research